Loading clinical trials...
Loading clinical trials...
Multicenter Phase II Single Arm Open-label Study on the Feasibility, Safety and Efficacy of Combination of CHOP-21 Supplemented With Obinutuzumab and Ibrutinib in Untreated Young High Risk Diffuse Large B-cell Lymphoma (DLBCL) Patients.
Conditions
Interventions
Obinutuzumab
Ibrutinib
+1 more
Locations
29
Italy
IRCCS Candiolo - Fondazione del Piemonte per l'oncologia
Candiolo, TO, Italy
AO SS. Antonio e Biagio e C. Arrigo
Alessandria, Italy
AOU Policlinico Consorziale
Bari, Italy
AO Papa Giovanni XXIII
Bergamo, Italy
Ospedale di Bolzano
Bolzano, Italy
Ospedale Businco
Cagliari, Italy
Start Date
September 1, 2016
Primary Completion Date
February 1, 2017
Completion Date
February 1, 2017
Last Updated
March 20, 2017
NCT04161248
NCT06528301
NCT05940272
NCT06534437
NCT05463263
NCT06609304
Lead Sponsor
Fondazione Italiana Linfomi - ETS
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions